Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 10/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.34 |
| ▸ | KDM5A | P29375 | 7/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420680 | 0.90 | KDM4C (0.39) | LTA4HKDM4CKDM5AKDM5CKDM5B | |
| SCHEMBL24614982 | 0.87 | MEN1 (0.58) | MEN1KMT2ALTA4HKDM5A | |
| SCHEMBL24614981 | 0.85 | BLM (0.32) | KDM4CKDM5APHF8 | |
| SCHEMBL26650890 | 0.84 | LTA4H (0.40) | LTA4HKDM4CKDM5AKDM5CKDM5B | |
| SCHEMBL20660409 | 0.82 | DRD2 (0.32) | — | |
| SCHEMBL31399552 | 0.81 | MEN1 (0.46) | MEN1KMT2ALTA4HKDM4CKDM5A | |
| SCHEMBL26962148 | 0.80 | — | — | |
| SCHEMBL6534167 | 0.80 | ALDH1A1 (0.34) | KDM5CPHF8 | |
| SCHEMBL20660298 | 0.80 | CHRNB2 (0.41) | — | |
| SCHEMBL5320462 | 0.79 | LMNA (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4256067-A2 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | Tidal Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220218614-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220218614-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2022120388-A2 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218614-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | LIPA, PHOSPHO1, SGMS1 | MEN1 2364/4885KMT2A 2113/4885LTA4H 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.